Dynavax (DVAX) slip on unfavorable drug news
Normal 0 false false false MicrosoftInternetExplorer4 Dynavax Technologies Corp. (NASDAQ: DVAX) shares slumped 2.5% to $4.64. Late Thursday, the company said that the U.S. Food and Drug Administration Vaccines and Related Biological Products Advisory Committee voted eight to five with one abstention that there was insufficient data to adequately support the safety of the firm’s hepatitis B vaccine product HEPLISAV. Share volume was 40,000 /* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-parent:""; mso-padding-alt:0in 5.4pt 0in 5.4pt; mso-para-margin:0in; mso-para-margin-bottom:.0001pt; mso-pagination:widow-orphan; font-size:10.0pt; font-family:"Times New Roman"; mso-ansi-language:#0400; mso-fareast-language:#0400; mso-bidi-language:#0400;}
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here